The oncostatic action of melatonin in an ovarian carcinoma cell line.
about
Melatonin and cancer risk: does light at night compromise physiologic cancer protection by lowering serum melatonin levels?Urinary melatonin and risk of ovarian cancerSirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer.Melatonin protects against oxidative stress caused by delta-aminolevulinic acid: implications for cancer reduction.Expression of the MT1 melatonin receptor in ovarian cancer cells.Melatonin attenuates the TLR4-mediated inflammatory response through MyD88- and TRIF-dependent signaling pathways in an in vivo model of ovarian cancerMelatonin, the circadian multioscillator system and health: the need for detailed analyses of peripheral melatonin signaling.Health consequences of shift work and implications for structural design.Melatonin-mediated Bim up-regulation and cyclooxygenase-2 (COX-2) down-regulation enhances tunicamycin-induced apoptosis in MDA-MB-231 cells.Melatonin induces transcriptional regulation of Bim by FoxO3a in HepG2 cells.Melatonin as a Promising Agent to Treat Ovarian Cancer: Molecular Mechanisms.Melatonin modulation of intracellular signaling pathways in hepatocarcinoma HepG2 cell line: role of the MT1 receptor.Oncostatic activity of a thiazolidinedione derivative on human androgen-dependent prostate cancer cells.Melatonin: Pharmacology, Functions and Therapeutic Benefits.Melatonin and Hippo Pathway: Is There Existing Cross-Talk?Inhibition of matrix metalloproteinase-9 and nuclear factor kappa B contribute to melatonin prevention of motility and invasiveness in HepG2 liver cancer cells.mt(1) Receptor-mediated antiproliferative effects of melatonin on the rat uterine antimesometrial stromal cells.Effects of exogenous melatonin and circadian synchronization on tumor progression in melanoma-bearing C57BL6 mice.Melatonin Synergizes the Chemotherapeutic Effect of Cisplatin in Ovarian Cancer Cells Independently of MT1 Melatonin Receptors.Melatonin inhibits MMP-9 transactivation and renal cell carcinoma metastasis by suppressing Akt-MAPKs pathway and NF-κB DNA-binding activity.Melatonin: An Anti-Tumor Agent in Hormone-Dependent CancersNeurobiology, pathophysiology, and treatment of melatonin deficiency and dysfunction
P2860
Q24645648-1340C3F9-41BA-4F28-8EDF-F738166AD577Q28388517-D3EDEC56-DE6B-4BC0-BE38-2FD022CDCFA7Q34168873-51ED651F-7F48-4B73-A755-44A0C46E84FDQ34569017-CA2D5F1F-5960-4857-AEFB-27C7A4DE6266Q34835245-82B58B1D-33E3-4FE8-AF2F-F5E5440A2482Q35066004-58C2F4B8-5024-418A-9D29-88E76D27F7F8Q37950409-411B8DD9-2739-4FE4-BD23-4FAC3FEB2148Q38093780-B5AD84FF-4F86-4B56-A0EC-7E03C87B33A6Q38906542-40306CDB-1B12-4095-B7B1-8AEE04E95009Q39222725-C02BF942-5C6B-49F0-A168-4138F1C78521Q39346336-12E5F449-E525-4E47-A63D-DB412D0EE673Q39515321-DCE2DEE9-8A97-4E23-86D2-096597908FBAQ40807764-7DC3D92E-7569-460A-A113-DF784713752AQ41638855-A1F1B625-6329-46E6-944C-CB2CA7F119A9Q41660894-17B3B847-BDD3-4564-8DAF-376AC0B58792Q43778009-412843DD-05AF-4C3A-A619-383CF6355B77Q43861910-A53C1649-5106-4365-994B-6068A7FD3A95Q46703444-809B59C2-4074-4C03-8F2E-368B33126FEBQ47169877-A39C88AE-6DFE-4F72-8C65-6FEE49862143Q54224159-FD4A9508-3A24-4B0D-857F-5D31AEB1DBF5Q58587207-F16B05CF-0EAC-401B-8B4A-F652C4B0875EQ58914961-721B4611-75C9-459C-B06D-C5DDD3CABD58
P2860
The oncostatic action of melatonin in an ovarian carcinoma cell line.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
The oncostatic action of melatonin in an ovarian carcinoma cell line.
@en
type
label
The oncostatic action of melatonin in an ovarian carcinoma cell line.
@en
prefLabel
The oncostatic action of melatonin in an ovarian carcinoma cell line.
@en
P2093
P2860
P1476
The oncostatic action of melatonin in an ovarian carcinoma cell line.
@en
P2093
P2860
P304
P356
10.1111/J.1600-079X.1999.TB00574.X
P577
1999-04-01T00:00:00Z